SciBase presents at Redeye Growth Day 2021

SciBase a leading developer of augmented intelligence-based solutions for skin disorders, announced today that CEO Simon Grant will, on June 2 at 8.50 am, present the latest developments in SciBase at the Redeye Growth Day 2021. The presentation will be broadcasted live and can be followed at https://www.redeye.se/events/808637/redeye-growth-day-2021 where it also will be available afterwards, and in parallel it will be made available at the Company's page on Redeye.se https://www.redeye.se/company/scibase-holding .

"*We have achieved many exciting and important milestones recently at SciBase. After a long process we received our MDR-certification which enabled us to launch our NMSC (non-melanoma skin cancer) application in Europe, which is a key part of our growth strategy. We have also entered a new phase in the US by submitting our first application for reimbursement coverage – another very important milestone for the company. Within the skin barrier application two significant and groundbreaking clinical studies have recently been published. Barrier-related diseases are widespread, and using Nevisense as a tool for the assessment of the barrier can really help better understand and manage patients,*" says Simon Grant, CEO SciBase.

For more information please contact:
Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: simon.grant@scibase.com

Certified Advisor:
Avanza
Tel: +46 8 409 421 20
Email: ca@avanza.se

About SciBase and Nevisense
SciBase AB is a global medical technology company based in Stockholm, Sweden that develops unique point-of-care devices for the evaluation of skin disorders such as skin cancer and atopic dermatitis. SciBase's first product, Nevisense, helps clinicians detect melanoma, the most dangerous type of skin cancer. Further development has led to Nevisense also being used as a tool to assess the skin barrier and non-melanoma skin cancer. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and an FDA approval (PMA) in the United States. SciBase technology is based Electrical Impedance Spectroscopy (EIS) combined with Artificial Intelligence (AI) algorithms that interpret the varying electrical properties of human tissue to detect malignancies and abnormalities. SciBase Holding AB is listed on First North Growth Market ("SCIB"). Further information is available at www.scibase.com.